



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Fecal Microbiota Transplantation

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 682

BCBSA Reference Number: 2.01.92 (For Plan internal use only)

NCD/LCD: N/A

Related Policies

Fecal Analysis in the Diagnosis of Intestinal Dysbiosis, [#556](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Fecal microbiota transplantation using a conventional compounded product may be considered **MEDICALLY NECESSARY** for treatment of individuals with recurrent *Clostridium difficile* infection under the following condition:

- There have been at least 2 recurrences that are refractory to standard antibiotic treatment.

Fecal microbiota transplantation using a commercially prepared FDA approved product* may be considered **MEDICALLY NECESSARY** for the treatment of individuals with recurrent *Clostridioides difficile* infection under the following condition:

- There have been at least 2 recurrences that are refractory to standard antibiotic treatment; and
- The recipient is 18 years of age or older.

Fecal microbiota transplantation is considered **INVESTIGATIONAL** in all other situations.

*In 2022, the FDA approved the first fecal microbiota product, Rebyota™ (fecal microbiota, live-jslm).⁶ Rebyota is approved for the prevention of recurrence of CDI in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. Importantly, the drug is not approved for the treatment of CDI. Rebyota is supplied as a 150 mL suspension for rectal administration as a single dose, 24 to 72 hours after the last dose of antibiotics for CDI.

*In 2023, the FDA approved the first orally administered fecal microbiota product, Vowst™ (fecal microbiota spores, live-brpk).⁷ Similar to Rebyota, Vowst is approved for the prevention of recurrence of

CDI in individuals 18 years of age and older following antibiotic treatment for recurrent CDI, and is not approved for the treatment of CDI. The drug is administered as 4 capsules by mouth once daily for 3 consecutive days.

Policy Guidelines

Use of a *conventional compounded product* refers to an FMT product not involving a stool bank where the FDA exercises enforcement discretion with respect to applicable investigational new drug (IND) requirements. For example, this may include FMT products prepared in a hospital laboratory under the direction of licensed health care providers for the purpose of treating their patients provided that the following requirements are met:

1. Physicians obtain adequate informed consent from patients or their legal representative before performing the intervention;
2. Providers perform appropriate screening and testing of the stool donor and stool; and
3. Procedures that mitigate potential safety concerns of FMT are followed.

There is a lack of consensus on the number of recurrences that warrants consideration of fecal microbiota transplantation (FMT).

The 2024 guidelines from the American Gastroenterological Association (AGA) for fecal microbiota-based therapies include 7 recommendations for the use of FMT in gastrointestinal diseases including *Clostridioides difficile* infection (CDI) (Peery et al, 2024; PMID 38395525). The guidelines consider FMT to be an option for immunocompetent individuals after the second recurrence (third episode). The AGA considers the degree of immunocompromise as a qualifier the use of CD in select individuals at high risk of either recurrent CDI or a morbid CDI recurrence. (See Supplemental Information) The AGA defined recurrent CDI as "clinically significant diarrhea with a confirmatory positive test within 8 weeks of completing antibiotics for CDI."

The 2021 focused update of the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guideline for CDI states that individuals with multiple recurrences of CDI who have failed to resolve their infection with standard of care antibiotic treatments are potential candidates for FMT (Johnson et al, 2021; PMID 34164674). It was the opinion of guideline panelists to have individuals try appropriate antibiotics for at least 2 recurrences (ie, 3 CDI episodes) before FMT is considered. The optimal timing between multiple FMT sessions is not discussed in the guidelines.

The 2021 American Society of Colon and Rectal Surgeons (ASCRS) guideline for CDI recommends that individuals with 3 or more CDI episodes be managed with a vancomycin tapered and pulsed course or fidaxomicin followed by a microbiome-based therapy such as FMT (Povlin et al, 2021; PMID 33769319). Per the guideline: "Conventional antibiotic treatment should be used for at least 2 recurrences (ie, 3 CDI episodes) before offering fecal microbiota transplantation." Per Table 3 in this guideline: for "Third or Subsequent" CDI episode: "If FMT is available, then 10-day course of vancomycin followed by FMT."

The 2021 American College of Gastroenterology (ACG) guideline for CDI recommends FMT for individuals experiencing their second or further recurrence of CDI (ie, third or later CDI episode) to prevent further recurrences (Kelly et al, 2021; PMID 34003176). This guideline also specifically recommends a repeat FMT for individuals experiencing a recurrence of CDI within 8 weeks of an initial FMT session.

Per the 2017 IDSA/SHEA guideline, a recurrent case occurs within 2 to 8 weeks of the incident case and requires both clinical plus laboratory evidence of disease for diagnosis; the 2021 IDSA/SHEA guideline does not provide an update to this definition. The 2021 guidelines from the ASCRS and ACG define a recurrent case as one occurring within 8 weeks after the completion of a course of CDI therapy and requiring both clinical plus laboratory evidence of disease for diagnosis (Povlin et al, 2017; PMID 33769319).

Due to the potential for serious adverse reactions with FMT, the U.S. Food and Drug Administration (FDA) has determined that the following protections are needed for use of FMT:

- Donor screening with questions that specifically address risk factors for colonization with multi-drug resistant organisms (MDROs), and exclusion of individuals at higher risk of colonization with MDROs.

- MDRO testing of donor stool and exclusion of stool that tests positive for MDRO. FDA scientists have determined the specific MDRO testing and frequency that should be implemented.
- Consent for the use of FMT is obtained from the individual or a legally authorized representative in accordance with FDA guidance (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota-0>).

On April 9, 2020, the FDA published additional safety information regarding the potential risk of transmission of SARS-CoV-2 via FMT. Recommendations for additional screening and testing procedures are outlined in this publication (<https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-new-safety-information-regarding-additional-protections-screening>).

On August 20, 2022, the FDA also published a safety alert regarding the use of FMT and additional safety protections pertaining to the monkeypox virus (<https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections-0>).

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .
Commercial PPO and Indemnity	Prior authorization is not required .
Medicare HMO Blue SM	Prior authorization is not required .
Medicare PPO Blue SM	Prior authorization is not required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above **medical necessity criteria MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
44705	Preparation of fecal microbiota for instillation, including assessment of donor specimen
0780T	Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract

HCPCS Codes

HCPCS codes:	Code Description
G0455	Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT and HCPCS codes above if medical necessity criteria are met:

ICD-10 Diagnosis Codes

ICD-10 CM diagnosis codes:	Code Description
A04.71	Enterocolitis due to <i>Clostridium difficile</i> , recurrent
A04.72	Enterocolitis due to <i>Clostridium difficile</i> , not specified as recurrent

DESCRIPTION

Fecal Microbiota

Fecal microbiota transplantation (FMT), also called donor feces infusion, intestinal microbiota transplantation, and fecal bacteriotherapy involves the duodenal infusion of intestinal microorganisms via the transfer of stool from a healthy individual into a diseased individual to restore normal intestinal flora. The stool can be infused as a liquid suspension into a patient's upper gastrointestinal tract through a nasogastric tube or gastroscopy, into the colon through a colonoscope or rectal catheter, or administered orally via capsules (ie, encapsulated FMT). Traditionally, the material used for FMT was prepared either within hospital facilities or at stool banks. More recently, FDA-approved FMT therapies have also come onto the market (see Regulatory Status section below).

The goal of FMT is to replace damaged and/or disordered native microbiota with a stable community of donor microorganisms. The treatment is based on the premise that an imbalance in the community of microorganisms residing in the gastrointestinal tract (i.e., dysbiosis) is associated with specific disease states, including susceptibility to infection.

The human microbiota, defined as the aggregate of microorganisms (bacteria, fungi, archaea) on and in the human body, is believed to consist of approximately 10 to 100 trillion cells, approximately 10 times the number of human cells. Most human microbes reside in the intestinal tract, and most of these are bacteria. In its healthy state, intestinal microbiota performs a variety of useful functions including aiding in the digestion of carbohydrates, mediating the synthesis of certain vitamins, repressing the growth of pathogenic microbes, and stimulating the lymphoid tissue to produce antibodies to pathogens.

Applications

Clostridioides difficile Infection

To date, the major potential clinical application of FMT is in the treatment of *Clostridioides difficile* infection (CDI). Infection of the colon with *C. difficile* is a major cause of colitis and can cause life-threatening conditions including colonic perforation and toxic megacolon. *C. difficile* occurs naturally in the intestinal flora. According to the 2019 Centers for Disease Control and Prevention (CDC) report, *Antibiotic Resistance Threats in the United States*, CDI continues to be an urgent threat.¹ In 2017, there were an estimated 223,900 cases of CDI in hospitalized patients and an estimated 12,900 CDI-associated deaths. Interestingly, the overall number of cases of healthcare-associated CDI cases has been trending down since 2012 when the number of cases was estimated at 251,400.

It is unclear what causes *C. difficile* overgrowth, but disruption of the normal colonic flora and colonization by *C. difficile* are major components. Disruption of the normal colonic flora occurs most commonly following the administration of oral, parenteral, or topical antibiotics. Standard treatment for CDI is antibiotic therapy. However, symptoms recur in up to 35% of patients, and up to 65% of patients with recurrences develop a chronic recurrent pattern of CDI.²

Other Applications

Other potential uses of FMT include the treatment of conditions in which altered colonic flora may play a role: inflammatory bowel disease, irritable bowel syndrome, idiopathic constipation, and non-gastrointestinal diseases such as multiple sclerosis, obesity, autism, and chronic fatigue syndrome. However, for these conditions, the contribution of alterations in colonic flora to the disorder is uncertain or controversial.

There is interest in alternatives to human feces that might have the same beneficial effects on intestinal microbiota without the risks of disease transmission. In a proof of principle study, Petrof et al (2013) evaluated a synthetic stool product in 2 patients with recurrent CDI.³ The product is made from 33 bacterial isolates developed from culturing stool from a healthy donor.

Summary

Summary

Description

Fecal microbiota transplantation (FMT) involves the administration of intestinal microorganisms via the transfer of stool from a healthy person into a diseased individual, with the intent of restoring normal intestinal flora. Fecal transplant is proposed for treatment-refractory *Clostridioides* (formerly *Clostridium*) *difficile* infection (CDI) and other conditions, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), pouchitis, constipation, multi-drug-resistant organism (MDRO) infection, or metabolic syndrome.

Summary of Evidence

For individuals who have recurrent *Clostridioides difficile* infection (CDI) refractory to antibiotic therapy who receive fecal microbiota transplantation (FMT) with a conventional compounded product, the evidence includes systematic reviews with meta-analyses and observational studies. Relevant outcomes are symptoms, change in disease status, and treatment-related morbidity. Meta-analyses have found that FMT is more effective than standard treatment or placebo for patients with recurrent CDI. A long-term prospective study found that FMT for recurrent or refractory CDI appears to be durable at 4 to 8 years following treatment, even for patients who had subsequently received non-CDI antibiotic therapy. A meta-analysis comparing several routes of FMT delivery for the treatment of recurrent CDI found that cure rates were significantly higher with colonoscopy or oral capsules versus nasogastric tube or enema, while colonoscopy and capsules were equally effective. Similar success rates have been demonstrated with FMT using fresh versus frozen feces. Conversely, data regarding the superiority of FMT using donor versus autologous feces are conflicting. Few treatment-related adverse events have been reported. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have recurrent *Clostridioides difficile* infection (CDI) refractory to antibiotic therapy who receive fecal microbiota transplantation (FMT) with an Food and Drug Administration (FDA)-approved product, the evidence includes randomized controlled trials (RCTs) and open-label studies. Relevant outcomes are symptoms, change in disease status, and treatment-related morbidity. The efficacy of an FDA-approved, rectally administered suspension containing live fecal microbiota spores was evaluated in a phase 3 double-blind, placebo-controlled RCT (PUNCH CD3; N=289), with analysis conducted using a Bayesian hierarchical model that borrowed data from a preceding phase 2b trial (PUNCH CD2; N=134). Both trials included adults with recurrent CDI (1 or more recurrences in PUNCH CD3, and 2 or more recurrences in PUNCH CD2) or a minimum of 2 CDI episodes within the preceding year that led to hospitalization, who received at least 10 consecutive days of standard antibiotic therapy and displayed improvement in CDI symptoms. The rate of treatment success, defined as the absence of CDI within 8 weeks of study treatment, was significantly higher in the group of patients who received rectally administered live fecal microbiota spores as compared to placebo (70.6% vs 57.5%). Additionally, among those patients who achieved treatment success at 8 weeks, more than 90% remained free of CDI recurrence through 6 months. In a single-arm, open-label trial evaluating FDA-approved rectal suspension containing live fecal microbiota spores, 91% of responders remained CDI free through 6 months. A phase 3, double-blind, placebo-controlled RCT (N=182) evaluated the efficacy of FDA-approved oral capsules containing live fecal microbiota spores in patients who had at least 2 recurrences within 12 months and who

received 10 to 21 consecutive days of standard antibiotic therapy and displayed improvement in CDI symptoms. Results demonstrated that a 3-day course of oral live fecal microbiota spores was more effective than placebo at preventing CDI recurrence within 8 weeks of treatment (12% vs 40%, respectively). In a single-arm, open-label trial evaluating FDA-approved oral capsules containing live fecal microbiota spores, the CDI recurrence rate at 24 weeks follow-up was 13.7%. Both orally and rectally administered FDA-approved FMT therapies were well-tolerated, with the majority of adverse events being mild-to-moderate in severity. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have inflammatory bowel disease (IBD) who receive FMT, the evidence includes systematic reviews and RCTs. Relevant outcomes are symptoms, change in disease status, and treatment-related morbidity. Systematic reviews have generally shown favorable clinical remission and response with FMT in patients with IBD while acknowledging that further RCTs and long-term follow-ups are needed to assess long-term effectiveness and safety. Additionally, a Cochrane review found that FMT did not significantly improve the maintenance of clinical or endoscopic remission of ulcerative colitis (UC). A 48-week RCT in patients with UC in clinical remission after prior FMTs found conflicting results for remission outcomes with additional courses of FMT. Another RCT in patients with recurrent active UC found a median remission time of 24 months in both FMT and standard of care treatment groups. A 12-month RCT evaluating FMT for the maintenance of remission in patients with UC did not find a statistically significant difference between single-dose FMT and control groups. This current evidence is not sufficient to permit conclusions on the efficacy of FMT for UC. Additionally, questions remain about the optimal route of administration, donor characteristics, and the number of transplants. An RCT in patients with Crohn disease (CD) failed to find a difference in the achievement of remission with FMT versus placebo. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have irritable bowel syndrome (IBS) who receive fecal microbiota transplantation (FMT) the evidence includes systematic reviews and RCTs. Relevant outcomes are symptoms, change in disease status, and treatment-related morbidity. For individuals who have IBS who receive FMT, the evidence includes systematic reviews and RCTs. Systematic reviews with meta-analyses have been inconsistent in finding improvements in clinical response, IBS Severity Scoring System, or IBS Quality of Life scores with FMT compared to placebo. Two additional RCTs also utilized autologous FMT as a placebo, and did not find a significant reduction in symptoms of IBS using donor FMT; both trials also found reduced durability of response 1 year following donor FMT. An additional placebo-controlled RCT used FMT delivered via oral capsules and found no improvement in abdominal pain scores, stool frequency, or stool form in a mixed population of patients with IBS. Few treatment-related adverse events have been reported. Data are limited by heterogeneity in utilized outcome measurement scales and definitions of treatment response. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have pouchitis, constipation, multi-drug-resistant organism (MDRO) infection, or metabolic syndrome who receive fecal microbiota transplantation (FMT), the evidence includes systematic reviews, RCTs, and prospective cohort studies. Relevant outcomes are symptoms, change in disease status, and treatment-related morbidity. Systematic reviews of data from patients who received FMT for constipation, pouchitis, MDRO infections, and metabolic syndrome have all concluded that more data are needed before FMT can be applied in clinical practice for these populations. In a meta-analysis assessing the use of FMT in obese and metabolic syndrome patients, the initial improvements of several metabolic parameters failed to demonstrate sustained durability at 12 weeks after treatment. While cohort studies have demonstrated FMT to be fairly effective in eradicating MDRO colonization, a RCT comparing FMT to no intervention in patients with MDROs failed to demonstrate improved rates of decolonization with treatment. An additional RCT in patients with chronic pouchitis concluded that the FMT regimen evaluated was not effective. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
------	--------

1/2025	Annual policy review. Policy updated with literature review through October 8, 2024; references added. Policy guidelines updated with 2024 AGA guidelines.
4/2024	Annual policy review. Policy updated with literature review through August 23, 2023; references added. Medically necessary policy statement added for commercially available FDA-approved FMT products, Rebyota and Vowst. Effective 4/1/2024.
1/2023	Clarified coding information. Annual policy review. Description, summary, and references updated. Minor editorial refinements to policy statements; intent unchanged.
1/2022	Annual policy review. Description, summary and references updated. Policy statements unchanged.
4/2021	Annual policy review. First policy statement updated with information from 2017 Infectious Diseases Society of America guidelines for C.diff regarding the number of prior C diff infections before fecal microbiota transplantation is considered (ie, "There have been at least 2 recurrences that are refractory to standard antibiotic treatment"). Effective 4/1/2021.
1/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2018	Annual policy review. New references added.
10/2017	Clarified coding information.
12/2016	Annual policy review. New references added.
1/2016	Annual policy review. New references added.
6/2015	Annual policy review. New references added.
10/2014	New policy describing medically necessary and investigational indications. Effective 10/1/2014.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
2. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. Nov 2011; 53(10): 994-1002. PMID 22002980
3. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome. Jan 09 2013; 1(1): 3. PMID 24467987
4. Food and Drug Administration (FDA). Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies. 2022; <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota> Accessed October 4, 2024.
5. Food and Drug Administration (FDA). Fecal Microbiota Transplantation: Safety Communication - Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms. 2019; <https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/fecal-microbiota-transplantation-safety-communication-risk-serious-adverse-reactions-due>. Accessed October 6, 2024.
6. FDA Approves First Fecal Microbiota Product. November 30, 2022. <https://www.prnewswire.com/news-releases/fda-approves-first-fecal-microbiota-product-301690762.html>. Accessed October 8, 2024.

7. FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of *Clostridioides difficile* Infection. April 26, 2023. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-orally-administered-fecal-microbiota-product-prevention-recurrence-clostridioides>. Accessed October 7, 2024.
8. Tariq R, Pardi DS, Bartlett MG, et al. Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection: A Systematic Review and Meta-analysis. *Clin Infect Dis*. Apr 08 2019; 68(8): 1351-1358. PMID 30957161
9. Rokkas T, Gisbert JP, Gasbarrini A, et al. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent *Clostridium difficile* infection. *United European Gastroenterol J*. Oct 2019; 7(8): 1051-1063. PMID 31662862
10. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis*. Mar 19 2018; 66(7): e1-e48. PMID 29462280
11. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of *Clostridioides difficile* Infection in Adults. *Clin Infect Dis*. Sep 07 2021; 73(5): e1029-e1044. PMID 34164674
12. Peery AF, Kelly CR, Kao D, et al. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. *Gastroenterology*. Mar 2024; 166(3): 409-434. PMID 38395525
13. Poylin V, Hawkins AT, Bhama AR, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of *Clostridioides difficile* Infection. *Dis Colon Rectum*. Jun 01 2021; 64(6): 650-668. PMID 33769319
14. Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of *Clostridioides difficile* Infections. *Am J Gastroenterol*. Jun 01 2021; 116(6): 1124-1147. PMID 34003176
15. Minkoff NZ, Aslam S, Medina M, et al. Fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* (*Clostridium difficile*). *Cochrane Database Syst Rev*. Apr 25 2023; 4(4): CD013871. PMID 37096495
16. Khan MY, Dirweesh A, Khurshid T, et al. Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent *Clostridium difficile* infection: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol*. Nov 2018; 30(11): 1309-1317. PMID 30138161
17. Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory *Clostridium difficile* infection. *Aliment Pharmacol Ther*. Sep 2017; 46(5): 479-493. PMID 28707337
18. Guo B, Harstall C, Louie T, et al. Systematic review: faecal transplantation for the treatment of *Clostridium difficile*-associated disease. *Aliment Pharmacol Ther*. Apr 2012; 35(8): 865-75. PMID 22360412
19. Sofi AA, Silverman AL, Khuder S, et al. Relationship of symptom duration and fecal bacteriotherapy in *Clostridium difficile* infection-pooled data analysis and a systematic review. *Scand J Gastroenterol*. Mar 2013; 48(3): 266-73. PMID 23163886
20. Chapman BC, Moore HB, Overbey DM, et al. Fecal microbiota transplant in patients with *Clostridium difficile* infection: A systematic review. *J Trauma Acute Care Surg*. Oct 2016; 81(4): 756-64. PMID 27648772
21. Drekonja D, Reich J, Gezahegn S, et al. Fecal Microbiota Transplantation for *Clostridium difficile* Infection: A Systematic Review. *Ann Intern Med*. May 05 2015; 162(9): 630-8. PMID 25938992
22. Mamo Y, Woodworth MH, Wang T, et al. Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent *Clostridium difficile* Infection. *Clin Infect Dis*. May 17 2018; 66(11): 1705-1711. PMID 29272401
23. Meighani A, Alimirah M, Ramesh M, et al. Fecal Microbiota Transplantation for *Clostridioides Difficile* Infection in Patients with Chronic Liver Disease. *Int J Hepatol*. 2020; 2020: 1874570. PMID 32047670
24. Tun KM, Hsu M, Batra K, et al. Efficacy and Safety of Fecal Microbiota Transplantation in Treatment of *Clostridioides difficile* Infection among Pediatric Patients: A Systematic Review and Meta-Analysis. *Microorganisms*. Dec 12 2022; 10(12). PMID 36557703

25. Du C, Luo Y, Walsh S, et al. Oral Fecal Microbiota Transplant Capsules Are Safe and Effective for Recurrent *Clostridioides difficile* Infection: A Systematic Review and Meta-Analysis. *J Clin Gastroenterol*. Apr 01 2021; 55(4): 300-308. PMID 33471490
26. Ramai D, Zakhia K, Fields PJ, et al. Fecal Microbiota Transplantation (FMT) with Colonoscopy Is Superior to Enema and Nasogastric Tube While Comparable to Capsule for the Treatment of Recurrent *Clostridioides difficile* Infection: A Systematic Review and Meta-Analysis. *Dig Dis Sci*. Feb 2021; 66(2): 369-380. PMID 32166622
27. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing *Clostridium difficile* infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. *Clin Infect Dis*. Jun 2014; 58(11): 1515-22. PMID 24762631
28. Gangwani MK, Aziz M, Aziz A, et al. Fresh Versus Frozen Versus Lyophilized Fecal Microbiota Transplant for Recurrent *Clostridium Difficile* Infection: A Systematic Review and Network Meta-analysis. *J Clin Gastroenterol*. Mar 01 2023; 57(3): 239-245. PMID 36656270
29. Lee CH, Steiner T, Petrof EO, et al. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. *JAMA*. Jan 12 2016; 315(2): 142-9. PMID 26757463
30. Lee CH, Chai J, Hammond K, et al. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory *Clostridioides difficile* infection with or without antibiotic exposure. *Eur J Clin Microbiol Infect Dis*. Sep 2019; 38(9): 1731-1735. PMID 31165961
31. Khanna S, Assi M, Lee C, et al. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent *Clostridioides difficile* Infection. *Drugs*. Oct 2022; 82(15): 1527-1538. PMID 36287379
32. Dubberke ER, Orenstein R, Khanna S, et al. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent *Clostridioides difficile* Infection. *Infect Dis Ther*. Feb 2023; 12(2): 703-709. PMID 36544075
33. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an Oral Microbiome Therapy for Recurrent *Clostridioides difficile* Infection. *N Engl J Med*. Jan 20 2022; 386(3): 220-229. PMID 35045228
34. Cohen SH, Louie TJ, Sims M, et al. Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent *Clostridioides difficile* Infection in a Randomized Clinical Trial. *JAMA*. Nov 22 2022; 328(20): 2062-2064. PMID 36260754
35. Sims MD, Khanna S, Feuerstadt P, et al. Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent *Clostridioides difficile* Infection: A Phase 3, Open-Label, Single-Arm Trial. *JAMA Netw Open*. Feb 01 2023; 6(2): e2255758. PMID 36780159
36. Feuerstadt P, Chopra T, Knapple W, et al. PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent *Clostridioides difficile* infection. *Clin Infect Dis*. Aug 24 2024. PMID 39180326
37. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol*. Mar 2019; 114(3): 384-413. PMID 30840605
38. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. Apr 2018; 113(4): 481-517. PMID 29610508
39. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology*. Jun 2021; 160(7): 2496-2508. PMID 34051983
40. Imdad A, Pandit NG, Zaman M, et al. Fecal transplantation for treatment of inflammatory bowel disease. *Cochrane Database Syst Rev*. Apr 25 2023; 4(4): CD012774. PMID 37094824
41. Tan XY, Xie YJ, Liu XL, et al. A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. *Evid Based Complement Alternat Med*. 2022; 2022: 8266793. PMID 35795291
42. Fehily SR, Basnayake C, Wright EK, et al. Fecal microbiota transplantation therapy in Crohn's disease: Systematic review. *J Gastroenterol Hepatol*. Oct 2021; 36(10): 2672-2686. PMID 34169565
43. Zhou HY, Guo B, Lufumpa E, et al. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. *Immunol Invest*. May 2021; 50(4): 323-337. PMID 32009472

44. Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *J Crohns Colitis*. Oct 01 2017; 11(10): 1180-1199. PMID 28486648
45. Lahtinen P, Jalanka J, Mattila E, et al. Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: A randomized controlled trial. *World J Gastroenterol*. May 07 2023; 29(17): 2666-2678. PMID 37213403
46. Crothers JW, Chu ND, Nguyen LTT, et al. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. *BMC Gastroenterol*. Jul 08 2021; 21(1): 281. PMID 34238227
47. Fang H, Fu L, Li X, et al. Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study. *Microb Cell Fact*. Jan 19 2021; 20(1): 18. PMID 33468164
48. Sokol H, Landman C, Seksik P, et al. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. *Microbiome*. Feb 03 2020; 8(1): 12. PMID 32014035
49. Sood A, Mahajan R, Singh A, et al. Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study. *J Crohns Colitis*. Sep 27 2019; 13(10): 1311-1317. PMID 30873549
50. Li Q, Ding X, Liu K, et al. Fecal Microbiota Transplantation for Ulcerative Colitis: The Optimum Timing and Gut Microbiota as Predictors for Long-Term Clinical Outcomes. *Clin Transl Gastroenterol*. Aug 2020; 11(8): e00224. PMID 32955197
51. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. *Am J Gastroenterol*. Jan 01 2021; 116(1): 17-44. PMID 33315591
52. Aziz I, Törnblom H, Palsson OS, et al. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. *Am J Gastroenterol*. Jul 2018; 113(7): 1017-1025. PMID 29880963
53. Ianiro G, Eusebi LH, Black CJ, et al. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther*. Aug 2019; 50(3): 240-248. PMID 31136009
54. Elhusein AM, Fadlalmola HA. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome Patients: An Updated Systematic Review and Meta-Analysis. *Gastroenterol Nurs*. Jan-Feb 2022; 45(1): 11-20. PMID 35108241
55. Wang M, Xie X, Zhao S, et al. Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. *Front Immunol*. 2023; 14: 1136343. PMID 37275867
56. Lo SW, Hung TH, Lin YT, et al. Clinical efficacy and safety of faecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis and trial sequential analysis. *Eur J Med Res*. Sep 18 2024; 29(1): 464. PMID 39289768
57. Madsen AMA, Halkjær SI, Christensen AH, et al. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study. *Scand J Gastroenterol*. Jul 2021; 56(7): 761-769. PMID 34000958
58. Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. *Gastroenterology*. Jan 2021; 160(1): 145-157.e8. PMID 32681922
59. Lahtinen P, Jalanka J, Hartikainen A, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. *Aliment Pharmacol Ther*. Jun 2020; 51(12): 1321-1331. PMID 32343000
60. Rossen NG, MacDonald JK, de Vries EM, et al. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. *World J Gastroenterol*. May 07 2015; 21(17): 5359-71. PMID 25954111
61. Cold F, Kousgaard SJ, Halkjaer SI, et al. Fecal Microbiota Transplantation in the Treatment of Chronic Pouchitis: A Systematic Review. *Microorganisms*. Sep 18 2020; 8(9). PMID 32962069
62. Zaman S, Akingboye A, Mohamedahmed AYY, et al. Faecal Microbiota Transplantation [FMT] in the Treatment of Chronic Refractory Pouchitis: A Systematic Review and Meta-analysis. *J Crohns Colitis*. Jan 27 2024; 18(1): 144-161. PMID 37450947

63. Saha S, Tariq R, Tosh PK, et al. Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review. *Clin Microbiol Infect.* Aug 2019; 25(8): 958-963. PMID 30986562
64. Proença IM, Allegretti JR, Bernardo WM, et al. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. *Nutr Res.* Nov 2020; 83: 1-14. PMID 32987284
65. Qiu B, Liang J, Li C. Effects of fecal microbiota transplantation in metabolic syndrome: A meta-analysis of randomized controlled trials. *PLoS One.* 2023; 18(7): e0288718. PMID 37471410
66. Karjalainen EK, Renkonen-Sinisalo L, Satokari R, et al. Fecal Microbiota Transplantation in Chronic Pouchitis: A Randomized, Parallel, Double-Blinded Clinical Trial. *Inflamm Bowel Dis.* Oct 20 2021; 27(11): 1766-1772. PMID 33501942
67. Huttner BD, de Lastours V, Wassenberg M, et al. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. *Clin Microbiol Infect.* Jul 2019; 25(7): 830-838. PMID 30616014
68. Bar-Yoseph H, Carasso S, Shklar S, et al. Oral Capsulized Fecal Microbiota Transplantation for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization With a Metagenomic Perspective. *Clin Infect Dis.* Jul 01 2021; 73(1): e166-e175. PMID 32511695
69. Seong H, Lee SK, Cheon JH, et al. Fecal Microbiota Transplantation for multidrug-resistant organism: Efficacy and Response prediction. *J Infect.* Nov 2020; 81(5): 719-725. PMID 32920061
70. Wang S, Xu M, Wang W, et al. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. *PLoS One.* 2016; 11(8): e0161174. PMID 27529553